Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Johnson & Johnson : Talcum Powder Lawsuit Plaintiffs Claim Unsealed Documents Show Johnson & Johnson Knew of Talc- Asbestos Danger in 1970s, Bernstein Liebhard LLP...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 07:32pm CET

Talcum Powder Lawsuit Plaintiffs Claim Unsealed Documents Show Johnson & Johnson Knew of Talc- Asbestos Danger in 1970s, Bernstein Liebhard LLP Reports

By a News Reporter-Staff News Editor at Women's Health Weekly -- Plaintiffs pursuing talcum powder lawsuits in Missouri state court claim that newly unsealed documents show that Johnson & Johnson has known since the 1970s that its talc-based powders contained asbestos fibers, which could increase the risk of ovarian cancer in women who used the products for daily feminine hygiene. (Case No. 1522-CC10417, Circuit Court, City of St. Louis, Missouri)

"Our Firm is representing women who allegedly developed ovarian cancer due to Johnson & Johnson's talcum powder products. These documents are of great interest to our clients, and we will continue to monitor the Missouri litigation for any other developments that could impact their claims," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices, drugs and consumer products. The Firm is offering free legal reviews to women who were diagnosed with ovarian cancer that may be associated with Johnson & Johnson'sBaby Powder and Shower-to-Shower products (see also Bernstein Liebhard Llp).

Keywords for this news article include: Talc, Asbestos, Oncology, Gynecology, Legal Issues, Silicic Acid, Women's Health, Silicon Dioxide, Silicon Compounds, Inorganic Chemicals, Magnesium Silicates, Risk and Prevention, Mixed Ovarian Cancer, Bernstein Liebhard Llp.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
02/23JNJ The Law Offices of Vincent Wong Notifies Investors of a Class Action Invo..
BU
02/23JOHNSON & JOHNSON : New TREMFYA® guselkumab Data Demonstrates Long-Term Skin Cle..
AQ
02/23JOHNSON & JOHNSON : Pawar Law Group Announces That a Class Action Lawsuit Has Be..
AC
02/23JOHNSON & JOHNSON : AMBER, Johnson & Johnson to establish 3D bioprinting lab
AQ
02/22JOHNSON & JOHNSON : Ireland to get its own dedicated 3D bioprinting lab to grow ..
AQ
02/22JOHNSON & JOHNSON : Medical Devices Companies Acquire Orthotaxy to Develop Next-..
AQ
02/22JOHNSON & JOHNSON : to Participate in Cowen 38th Annual Healthcare Conference
AQ
02/22JOHNSON & JOHNSON : Sharing is caring
AQ
02/21JOHNSON & JOHNSON : MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATION..
AQ
02/21Levi & Korsinsky, LLP Notifies Shareholders of Johnson & Johnson of Commencem..
BU
More news
News from SeekingAlpha
02/24RETIREMENT STRATEGY : What The Heck Are You Waiting For? 
02/22GE : Keeping Management 'Honest' On 2018 Guidance - Share Price Could Go To $10 
02/22Upcoming Dividends; 89 Companies, 32 Increases, 14 Double-Digit Increases 
02/22Volatility And Your Retirement Plan 
02/21Tracking Tweedy Browne Portfolio - Q4 2017 Update 
Financials ($)
Sales 2018 81 103 M
EBIT 2018 24 826 M
Net income 2018 19 539 M
Debt 2018 11 371 M
Yield 2018 2,79%
P/E ratio 2018 18,02
P/E ratio 2019 16,84
EV / Sales 2018 4,44x
EV / Sales 2019 4,08x
Capitalization 349 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 151 $
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-7.02%349 006
NOVARTIS-2.94%222 939
PFIZER-1.33%213 155
ROCHE HOLDING LTD.-9.41%207 036
MERCK AND COMPANY-3.02%148 618
AMGEN4.92%132 428